
Why Companies Are Losing AI Talent — And How Leaders Can Stop It
Companies keep blaming the AI talent shortage on competition and compensation. But the real problem ... More may lie within — in rigid cultures, outdated leadership and a failure to build environments where AI professionals actually want to stay.
'We can't find enough AI talent.' That's one of the major dilemmas in boardrooms around the world right now, as AI continues on an upward trajectory. The job postings are live, compensation is competitive and tools are top-tier. Yet still, machine learning engineers and data scientists walk away — or worse, never apply for these roles.
But what if this isn't a hiring crisis at all? What if it's a leadership one?
While the spotlight has been on salaries and skills shortages, some experts argue that it isn't just that AI professionals are hard to hire, but also that they're easy to lose. The argument is that this phenomenon isn't because these professionals aren't engaged with the work, but because the environment they're asked to work in is often fundamentally misaligned with how AI innovation thrives.
'AI professionals' rare expertise gives them unprecedented leverage in today's market,' noted Erika Glenn, a C-suite executive and board advisor. 'They can command high compensation while prioritizing workplace flexibility elsewhere. Many companies maintain rigid policies under leadership that rarely understands AI culture's unique needs — and that disconnect pushes experts to leave.'
The case today, at least for a large chunk of the industry, is that AI talent isn't chasing ping-pong tables or inflated job titles. They're going after meaning, autonomy and a future-focused mission. When they don't find that, they leave — often to start their own ventures or join smaller companies with more adaptive cultures.
According to Michelle Machado, a neurochange solutions consultant and global educator, the deeper issue lies with legacy mindsets. 'Too many leaders are still operating with 20th-century thinking while trying to compete in a 21st-century AI race,' she told me in an interview. 'It's like watching companies in the year 2000 debate whether they needed a website.'
Machado pointed to a telling stat: nearly 40% of companies are failing at AI implementation because leadership doesn't understand its potential. This misunderstanding manifests in all the wrong ways — treating AI like a side project, demanding office-based routines for remote-ready work, or imposing waterfall processes on what should be experimental systems.
Glenn added that many leaders 'still treat AI development like traditional software engineering, enforcing rigid schedules and micromanagement that stifle innovation.' That kind of control-heavy approach repels the very minds companies are desperate to retain.
Worse, it builds resentment. When leadership demands agility from tech teams but clings to bureaucracy in its own decision-making, AI experts read the signal loud and clear: this is not a place where real innovation is welcome.
A common misconception is that AI professionals are simply poached by bigger paychecks. But Machado challenges that. 'Unless leaders build a culture of experimentation, collaboration, and future-focused thinking, even the best AI hires won't stay,' she said. 'It's culture, not just compensation, that ultimately attracts and retains top talent.'
Glenn agrees, noting that great leaders 'foster cultures of open dialogue and shared incentives, where controversial viewpoints are welcomed without repercussion.' They balance autonomy with accountability, shield teams from politics and reward experimentation, even when it fails.
That environment is rare. But when it exists, it creates gravity that retains talent. And the organizations drawing and keeping the brightest AI minds are the ones with that kind of gravity, necessarily those with the most advanced models.
When it comes to retaining talent, Machado's advice is that transparency is what fuels trust. 'People stay when they understand the impact of their work and how it connects to broader business outcomes,' she said. In a field as cross-functional and fast-paced as AI, where models must touch operations, compliance, customer data and ethics, that transparency must be baked into every layer of leadership.
It also requires vulnerability; a willingness to admit what the company doesn't yet know and a commitment to build that knowledge together. 'When people feel seen, heard and valued,' Machado explained, 'they don't just contribute — they commit.'
This is especially vital in large enterprises, where AI efforts often suffocate under organizational silos. 'Silos don't just slow innovation,' she added. 'They stall transformation.'
Losing a top AI engineer doesn't just mean opening another job requisition — it sets off a chain reaction. Projects stall, morale dips and, perhaps worst of all, institutional knowledge walks out the door.
'Replacing technical professionals can cost between one-half to two times their annual salary,' said Glenn, citing Gallup. SHRM confirms these costs across industries, especially in high-skill domains like AI and cybersecurity. But the true impact isn't financial alone. 'Team morale deteriorates, skillset imbalances emerge, and product development suffers,' she warned.
Machado put it bluntly: 'Failing to retain AI talent comes at a steep price, not just in turnover, but in missed relevance.' She compared it to the cautionary tales of Kodak and Blockbuster — companies that didn't fail for lack of talent, but for lack of leadership readiness. 'In this market, you either evolve or dissolve. There is no middle ground.'
Machado's argument isn't exaggerated at all, according to the stats. In a 2024 Bain & Company survey, 75% of executives admitted they don't fully understand how to scale AI within their organizations. And that uncertainty at the top trickles down — creating friction, confusion and eventually, flight.
So what makes AI talent stay? Both Glenn and Machado agree that it's not just about technical ability but about how leaders show up.
'The best leaders create environments of genuine autonomy,' Glenn said. 'They demonstrate problem-solving engagement, regardless of their technical depth, shield their teams from politics, balance accountability with empowerment and treat failure as an important part of the process.'
For Machado, great leadership begins with trust and human connection. 'AI may run on data, but exceptional outcomes still run on trust,' she said. 'When leaders share purpose, invite diverse perspectives and celebrate progress over perfection, teams move from compliance to commitment.' In these types of environments, AI professionals don't just build better models — they build momentum, innovate and, most importantly, stay.
The bottom line is that there's no AI strategy without a talent strategy — and no talent strategy without leadership. Yes, compensation still matters and the global shortage of AI professionals is real. But throwing more money at the problem won't fix a culture that's broken. Attracting and retaining AI talent is not just about who you hire, but more about how you lead.
The AI talent gap, according to Machado, isn't simply a hiring problem — it's a leadership one. She added that 'this problem at its core is about trust: trust in your people, in your strategy and in your capacity to lead through change.'
If AI companies want to stay competitive, the message from Glenn and Machado is that they'll need more than advanced models. They'll need leaders who can think forward, act with empathy and build environments where AI professionals can thrive.
'Innovation stalls when leadership fails. But with the right leadership? AI becomes a force multiplier, not a flight risk,' Glenn said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Drug maker Indivior to abandon London stock market for the US
Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2 billion. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. 'We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' The LSE faced the largest exodus of companies since the global financial crisis in 2024, according to EY analysis. There were 88 companies to delist or transfer their primary listing from the main market – the most since 2009. At the same time, the LSE struggled to attract as many new companies to fill the gaps – with 18 new listings in total last year. Nevertheless, Indivior's exit, which will take effect from July 25, comes as Valterra Platinum makes its debut on the London market. Anglo American spun off its platinum business into the new entity, which has become the world's most valuable producer of the metal. Valterra will have its secondary listing on the LSE, with its primary on the Johannesburg Stock Exchange. Duncan Wanblad, Anglo American's chief executive, said: 'Valterra Platinum has been a major part of the company for many years but now is the right time for it to optimise its value creation prospects on an independent path – it's an outstanding business and team and I have every confidence that Valterra Platinum will thrive as a leader in the global platinum group metals industry.' Sign in to access your portfolio


Forbes
18 minutes ago
- Forbes
China Accuses US Of Violating Trade Pact—Rejects Trump's Allegation
Chinese authorities on Monday accused the U.S. of violating a recent trade pact that both agreed to in Geneva last month, as they dismissed President Donald Trump's allegation about Beijing breaching the agreement, a move that could signal a further escalation in trade tensions between the two countries, which could potentially jeopardize last month's tariff truce. China's Commerce Ministry accused the U.S. of violating a trade deal agreed in Geneva by imposing ... More additional chip restrictions and canceling Chinese student visas. In a press briefing, a Chinese Commerce Ministry spokesperson dismissed Trump's comments accusing China of violating the agreement, saying Beijing has worked 'to strictly implement and actively safeguard the Geneva deal.' The spokesperson noted that China had acted in accordance with the deal to cancel or suspend 'relevant tariffs and non-tariff measures' it had taken as retaliation against the U.S. government's reciprocal tariffs. The spokesperson then accused the U.S. of introducing ' a number of discriminatory restrictive measures against China' after the talks, citing expanded export controls on AI chips and other chip-building technology. The official also criticized the U.S. government's crackdown on Chinese student visas, saying these actions violated the consensus reached between Trump and Chinese President Xi Jinping in a phone call on January 17. The spokesperson then warned that if the U.S. continues to take actions that damage China, Beijing will 'take resolute and forceful measures to safeguard its legitimate rights and interests.' In a post on his Truth Social platform on Friday, Trump said: 'China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US,' without specifying how it had done so. The president then signalled that the U.S. may retaliate against this alleged non-compliance, saying: 'So much for being Mr. NICE GUY!' In his post, the president claimed his tariffs had put China in 'grave economic danger' and he made a 'FAST DEAL' in Geneva, 'in order to save them from what I thought was going to be a very bad situation.'
Yahoo
18 minutes ago
- Yahoo
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence Therapeutics' initial physical presence in the United States, reinforcing its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters. The new laboratory, located at Cambridge Scientific Labs in Watertown, will allow Defence Therapeutics to further develop and optimize its proprietary Accum® technology for antibody-drug conjugates ("ADCs"). Establishing a presence in the Boston-Cambridge area provides the company with access to top-tier scientific resources and opportunities for collaboration within the region's renowned biotech ecosystem. The Cambridge Scientific Labs location will serve as a short-term base while Defence Therapeutics evaluates options for a long-term facility in the area. "Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics," said Sebastien Plouffe, CEO of Defence Therapeutics. "Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum® platform for next-generation ADCs. We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market." About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information: Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data